Alnylam Launches Novel RNAi Therapeutic Onpattro (patisiran) in Germany

 Alnylam Launches Novel RNAi Therapeutic Onpattro (patisiran) in Germany

Alnylam Launches Novel RNAi Therapeutic Onpattro (patisiran) in Germany

Shots:

  • EU approval is based on results of APOLLO P-III study involving 19 countries in ratio (2:1) assessing Onpattro vs PBO once q3w for 18mos showing safety and efficacy
  • Onpattro RNA interference (RNAi) will be launch in Germany for the treatment of Hereditary Transthyretin-Mediated (hATTR) with improved QoL
  • Onpattro is an IV RNAi therapeutic developed to treat Amyloidosis (hATTR Amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy. It is based on RNAi, a Nobel Prize-winning Mechanism and received EU and FDA approval in Aug 2018

Click here to read full press release/ article | Ref: Alnylam | Image: BusinessWire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post